FOXP3 and type 1 diabetes mellitus: Treg adoptive transfer therapies have shown promising outcomes, for instance, in patients with type 1 diabetes (53) or in patients with amyotrophic lateral sclerosis, which is a neurological disease wherein FOXP3-expressing cells decrease with disease progression (54).